Capital Point: What the Chief Scientist Loans Really Mean for Liquidity
At Capital Point, NIS 23.0 million of old Chief Scientist loans sit inside current liabilities and compress the headline liquidity read. This follow-up shows why that balance sheet signal is misleading, but also why it is still a live liability that cannot be waved away.
Where The Balance Sheet Misleads
The main article argued that Capital Point should not be read only through NAV, but through its ability to bring cash home. This follow-up isolates one line that distorts the first balance-sheet read, Chief Scientist loans. At the end of 2025 they stood at NIS 23.0 million out of total current liabilities of NIS 26.0 million. In other words, almost the entire current-liability side comes from one old and unusual item, not from ordinary operating payables or from fresh bank debt.
This is not a cosmetic detail. The standard balance-sheet headline shows working capital of NIS 47.4 million and a current ratio of 2.82. Those are reasonable numbers, but they do not suggest an exceptional cushion. Yet the company itself also presents the picture after excluding the Chief Scientist loans from current liabilities, and then working capital jumps to NIS 70.4 million while the current ratio rises to 24.45. That is more than a NIS 23 million swing in the working-capital picture.
That matters because it blocks two opposite misreads. The first is to look at NIS 26 million of current liabilities and conclude that Capital Point is moving toward a normal near-term repayment wall. The second is to notice that this is legacy state debt and dismiss it as accounting noise. Neither read is right. The line does distort the liquidity picture, but it is also a real liability that is still growing.
That is clearest in the 2025 movement table. The Chief Scientist balance rose from NIS 21.6 million to NIS 23.0 million, with no repayment at all, and only because of NIS 1.398 million of interest and indexation. That is the core point. Even if this liability does not behave like a regular bank line, it still eats into flexibility through CPI linkage and finance cost.
What This Debt Actually Is
To understand why the full line sits in current liabilities, the history matters. By the end of 2025 the group no longer had state loans used to finance project companies. Over the years the subsidiaries elected not to repay or defer those balances, as the framework allowed, which meant transferring shares to the state according to the state's share of the original financing. As of year-end that transfer had still not been completed because the relevant government body had not yet provided the mechanism for carrying it out.
What remains on the balance sheet is something else, old state financing that was used to fund the operation of the incubators themselves. The repayment mechanics there are different. The state funded up to 49% of fixed operating expenses of the incubator, up to NIS 1.26 million, and the loan was meant to be repaid at the earliest of three paths, seven years from the start of operations, at least 25% of realization proceeds until full repayment, or enforcement of the pledge over the operating shares the incubator held in project companies.
| Item | What remained at end-2025 | Why it matters |
|---|---|---|
| State loans for project companies | None remained | This explains why the balance that is left is not active funding for the current portfolio |
| State loans for incubator operations | NIS 23.013 million | This is the balance that still sits in full inside current liabilities |
| Main collateral | Pledge over shares in project companies | This is the only collateral explicitly described for the Chief Scientist loans |
| Nature of the 2025 increase | NIS 1.398 million of interest and CPI linkage, with no repayment | The liability keeps accruing even without new borrowing |
This is the key analytical point. The remaining balance has no direct link to the 2025 investment cycle. It was not raised to add to Nasus, to buy more marketable securities or to fund a new round in one of the portfolio companies. These are leftovers from a much older incubator model, with original due dates in 2010, 2012 and 2015. So anyone reading the full NIS 23 million as if it were created against the operating risk of 2026 is missing the story.
But anyone who quickly waves it away as old baggage is missing the story too. The company states explicitly that because the original due dates passed long ago and the loans were not repaid, they are presented at full liability value, including accrued interest payable. Time is not cleaning up this line. Time is increasing it.
How It Changes The Liquidity Read
The right way to read this line is not as debt that can be ignored, but as debt that is fully classified into the short-term bucket and therefore weighs heavily on the liquidity picture. The liquidity table makes that very clear. Out of total projected cash flows of NIS 26.025 million due within one year, NIS 23.013 million relate to the Chief Scientist loans. All other current obligations together, suppliers, accruals and leases, amount to only about NIS 3.0 million.
That means the headline current-liability number says less about ordinary operations and more about the classification of legacy debt. A current ratio of 2.82 does not really describe normal pressure from suppliers, payroll, rent or a short bank facility. It describes a balance sheet where one old and unusual line item sits almost alone on the current-liability side.
That still does not make Capital Point a company with completely free cash. At the end of 2025 it had NIS 25.9 million of cash and cash equivalents and another NIS 5.35 million of short-term deposits, against NIS 38.5 million of marketable securities. At the same time the company says its main funding sources are cash, short-term deposits and realizations of investments, not a new debt facility. That supports the view that the legacy state debt does not by itself create an immediate repayment wall. But there are two important caveats.
The first is that not all of that liquidity sits fully free. The company has a first-ranking fixed charge over all assets held in its International Bank account for the purpose of obtaining bank credit, and the charged amount, cash and securities, stood at about NIS 7.2 million at the reporting date. In addition, there was a pledged deposit of about NIS 138 thousand relating to a guarantee. Even if that deposit was released after the balance-sheet date, it is still a reminder that not every shekel on the balance sheet is equally available.
The second is that this debt keeps working against the company even without a new repayment demand. The 2025 movement shows that the balance grew by roughly 6.5% through interest and indexation alone. In addition, the company's sensitivity table shows a NIS 1.142 million pre-tax hit to profit in a scenario of a 5% increase in the CPI. That sensitivity test relates to the broader financial book, not only to the Chief Scientist loans, so it would be wrong to attribute all of it to this single line. Even so, it reinforces the point that CPI linkage is not some frozen historical footnote. It is still economically live in 2025.
This is exactly what the market can miss if it looks only at the drop in cash against current liabilities. Cash fell from NIS 37.7 million to NIS 25.9 million, which looks less comfortable when set against NIS 26 million of current liabilities. But inside that number sits an old liability that explains almost the whole gap. So the right read is a two-sided one, liquidity is less pressured than the first balance-sheet headline implies, but it is also less clean than a mechanical exclusion of the line would suggest.
Bottom Line
Capital Point's Chief Scientist loans are not a footnote, and they are not normal debt either. They sit in the middle, a legacy liability that is still alive, still accruing interest and indexation, still occupying almost the entire current-liability side and still making the liquidity picture look harsher than the underlying operating obligations really are.
The practical meaning is simpler than the headline suggests. Anyone who treats the NIS 23 million as if it were a fresh operating repayment wall is being too harsh. Anyone who treats it as if it had no remaining economic meaning is being too relaxed. The more disciplined read is that Capital Point still holds a meaningful liquid-asset cushion, but it has to manage that cushion on top of an old overhang that has not gone away and that still demands monetizations, cash discipline and much clearer progress toward resolution.
That is also where the next test comes from. For this line to stop being a recurring source of skepticism, it is not enough for the market backdrop to remain friendly. Capital Point will have to show one of two things, and ideally both, either that the balance starts to decline in practice, or that realizations and free liquidity grow faster than the interest and CPI drag on that balance. Until that happens, the balance-sheet discount will keep getting fuel from a line that was born many years ago.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.